NJK14047 is a drug which acts as a selective inhibitor of the enzyme p38 mitogen-activated protein kinase (p38 MAPK). It has antiviral and antiinflammatory effects and was originally developed as a potential treatment for inflammatory lung conditions such as influenza. Subsequent research has also shown promise for various other conditions in which inflammation plays a role, including Alzheimer's disease, asthma, arthritis and psoriasis.[1][2][3][4]
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C27H27NO5 |
| Molar mass | 445.515 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
editReferences
edit- ^ Choi MS, Heo J, Yi CM, Ban J, Lee NJ, Lee NR, et al. (August 2016). "A novel p38 mitogen activated protein kinase (MAPK) specific inhibitor suppresses respiratory syncytial virus and influenza A virus replication by inhibiting virus-induced p38 MAPK activation". Biochemical and Biophysical Research Communications. 477 (3): 311–316. doi:10.1016/j.bbrc.2016.06.111. PMID 27346133.
- ^ Gee MS, Son SH, Jeon SH, Do J, Kim N, Ju YJ, et al. (April 2020). "A selective p38α/β MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5XFAD mouse". Alzheimer's Research & Therapy. 12 (1): 45. doi:10.1186/s13195-020-00617-2. PMC 7175487. PMID 32317025.
- ^ Lee JH, Son SH, Kim NJ, Im DS (March 2023). "NJK14047 Suppression of the p38 MAPK Ameliorates OVA-Induced Allergic Asthma during Sensitization and Challenge Periods". Biomolecules & Therapeutics. 31 (2): 183–192. doi:10.4062/biomolther.2022.078. PMC 9970832. PMID 36171179.
- ^ Lee JH, Lee JE, Son SE, Son SH, Kim NJ, Im DS (March 2024). "NJK14047 inhibition of p38 MAPK ameliorates inflammatory immune diseases by suppressing T cell differentiation". International Immunopharmacology. 130: 111800. doi:10.1016/j.intimp.2024.111800. PMID 38447416.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |